Resolving inflammation
at its core
Citryll is pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Extracellular Traps (ETs), a fundamental driver of inflammation that has yet to be addressed therapeutically. Citryll is developing the first ET-targeting therapy, with the potential to establish a new therapeutic class for immune-mediated inflammatory diseases.
Targeting an unaddressed biology for treatment of immune mediated inflammatory disorders
Citryll is targeting ETs as a fundamental driver of inflammation in many immune mediated inflammatory diseases, with a focus on rheumatoid arthritis (RA) and hidradenitis suppurativa (HS) as therapeutic development areas for CIT-013. Our lead asset, CIT-013, is a first-in-class monoclonal antibody with a unique dual mechanism of action. CIT-013 has demonstrated a powerful ability to inhibit ET formation and enhance ET clearance, addressing a key component of inflammation. By intervening in this process, CIT-013 aims to overcome the limitations of therapies that target individual cytokines or downstream pathways.
Latest news
Exploring the Emerging Role of Extracellular Traps in Immune-Mediated Inflammatory Diseases
Earlier this week, Citryll hosted an educational webinar bringing together leading scientific and clinical experts to discuss the evolving understanding...
Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013
Expected to provide exclusivity into 2039 Oss, Netherlands – 15 April 2026 – Citryll, a biotech company pioneering a transformative...
Latest publications
Immunothrombosis Promotes The Interaction Between Neutrophils And Synovial Fibroblasts In Rheumatoid Arthritis
Phase I trial in participants with rheumatoid arthritis and healthy volunteers with CIT 013, a first-in-class extracellular traps targeted therapy
Conference calendar
Clinical trial opportunities for patients
Citryll is conducting clinical trials for CIT-013, an investigational therapy developed to address Rheumatoid Arthritis (RA) and Hidradenitis Suppurativa (HS). This clinical research seeks to understand CIT-013’s potential effectiveness, safety, and impact on patient quality of life. We expect two clinical trials to start by mid 2025.